214 related articles for article (PubMed ID: 37488701)
21. A comparison of live birth rates and perinatal outcomes between cryopreserved oocytes and cryopreserved embryos.
Ho JR; Woo I; Louie K; Salem W; Jabara SI; Bendikson KA; Paulson RJ; Chung K
J Assist Reprod Genet; 2017 Oct; 34(10):1359-1366. PubMed ID: 28718080
[TBL] [Abstract][Full Text] [Related]
22. [Clinical effects of oocyte cryopreservation in assisted reproduction technology].
Wang W; Yan ZJ; Cai LB; Chai DC; Liu CZ; Mao YD; Liu JY
Zhonghua Yi Xue Za Zhi; 2008 Oct; 88(39):2755-8. PubMed ID: 19080449
[TBL] [Abstract][Full Text] [Related]
23. Enhancing the scope of in vitro maturation for fertility preservation: transvaginal retrieval of immature oocytes during endoscopic gynaecological procedures.
Song XL; Lu CL; Zheng XY; Nisenblat V; Zhen XM; Yang R; Li M; Li R; Yuan YF; Ma CH; Liu P; Feng HL; Yan J; Qiao J
Hum Reprod; 2020 Apr; 35(4):837-846. PubMed ID: 32154563
[TBL] [Abstract][Full Text] [Related]
24. A Japanese nationwide survey on the cryopreservation of embryos, oocytes and ovarian tissue for cancer patients.
Sanada Y; Harada M; Kunitomi C; Kanatani M; Izumi G; Hirata T; Fujii T; Suzuki N; Morishige KI; Aoki D; Irahara M; Tsugawa K; Tanimoto M; Nishiyama H; Hosoi H; Sugiyama K; Kawai A; Osuga Y
J Obstet Gynaecol Res; 2019 Oct; 45(10):2021-2028. PubMed ID: 31364239
[TBL] [Abstract][Full Text] [Related]
25. Similar in vitro maturation rates of oocytes retrieved during the follicular or luteal phase offer flexible options for urgent fertility preservation in breast cancer patients.
Grynberg M; Poulain M; le Parco S; Sifer C; Fanchin R; Frydman N
Hum Reprod; 2016 Mar; 31(3):623-9. PubMed ID: 26759139
[TBL] [Abstract][Full Text] [Related]
26. Oocyte Cryopreservation in Oncological Patients: Eighteen Years Experience of a Tertiary Care Referral Center.
Specchia C; Baggiani A; Immediata V; Ronchetti C; Cesana A; Smeraldi A; Scaravelli G; Levi-Setti PE
Front Endocrinol (Lausanne); 2019; 10():600. PubMed ID: 31551931
[No Abstract] [Full Text] [Related]
27. Added Benefit of Immature Oocyte Maturation for Fertility Preservation in Women with Malignancy.
Cohen Y; Tannus S; Volodarsky-Perel A; Son WY; Tulandi T; Buckett W
Reprod Sci; 2020 Dec; 27(12):2257-2264. PubMed ID: 32617879
[TBL] [Abstract][Full Text] [Related]
28. A prospective study of women and girls undergoing fertility preservation due to oncologic and non-oncologic indications in Sweden-Trends in patients' choices and benefit of the chosen methods after long-term follow up.
Rodriguez-Wallberg KA; Marklund A; Lundberg F; Wikander I; Milenkovic M; Anastacio A; Sergouniotis F; Wånggren K; Ekengren J; Lind T; Borgström B
Acta Obstet Gynecol Scand; 2019 May; 98(5):604-615. PubMed ID: 30723910
[TBL] [Abstract][Full Text] [Related]
29. Ovarian response and follow-up outcomes in women diagnosed with cancer having fertility preservation: Comparison of random start and early follicular phase stimulation - cohort study.
Muteshi C; Child T; Ohuma E; Fatum M
Eur J Obstet Gynecol Reprod Biol; 2018 Nov; 230():10-14. PubMed ID: 30227359
[TBL] [Abstract][Full Text] [Related]
30. Delivery rate using cryopreserved oocytes is comparable to conventional in vitro fertilization using fresh oocytes: potential fertility preservation for female cancer patients.
Grifo JA; Noyes N
Fertil Steril; 2010 Feb; 93(2):391-6. PubMed ID: 19439285
[TBL] [Abstract][Full Text] [Related]
31. In vitro maturation improves oocyte or embryo cryopreservation outcome in breast cancer patients undergoing ovarian stimulation for fertility preservation.
Oktay K; Buyuk E; Rodriguez-Wallberg KA; Sahin G
Reprod Biomed Online; 2010 May; 20(5):634-8. PubMed ID: 20219430
[TBL] [Abstract][Full Text] [Related]
32. Combination of ovarian tissue harvesting and immature oocyte collection for fertility preservation increases preservation yield.
Hourvitz A; Yerushalmi GM; Maman E; Raanani H; Elizur S; Brengauz M; Orvieto R; Dor J; Meirow D
Reprod Biomed Online; 2015 Oct; 31(4):497-505. PubMed ID: 26278808
[TBL] [Abstract][Full Text] [Related]
33. Cryopreservation of in vitro matured oocytes in addition to ovarian tissue freezing for fertility preservation in paediatric female cancer patients before and after cancer therapy.
Abir R; Ben-Aharon I; Garor R; Yaniv I; Ash S; Stemmer SM; Ben-Haroush A; Freud E; Kravarusic D; Sapir O; Fisch B
Hum Reprod; 2016 Apr; 31(4):750-62. PubMed ID: 26848188
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of controlled ovarian stimulation using GnRH antagonist protocols for emergency fertility preservation in young women with breast cancer-a prospective nationwide Swedish multicenter study.
Marklund A; Eloranta S; Wikander I; Kitlinski ML; Lood M; Nedstrand E; Thurin-Kjellberg A; Zhang P; Bergh J; Rodriguez-Wallberg KA
Hum Reprod; 2020 Apr; 35(4):929-938. PubMed ID: 32313940
[TBL] [Abstract][Full Text] [Related]
35. Fertility after breast cancer treatment.
Kasum M; Beketić-Orešković L; Peddi PF; Orešković S; Johnson RH
Eur J Obstet Gynecol Reprod Biol; 2014 Feb; 173():13-8. PubMed ID: 24315568
[TBL] [Abstract][Full Text] [Related]
36. Experiences in fertility preservation: lessons learned to ensure that fertility and reproductive autonomy remain options for cancer survivors.
Noyes N; Melzer K; Druckenmiller S; Fino ME; Smith M; Knopman JM
J Assist Reprod Genet; 2013 Oct; 30(10):1263-70. PubMed ID: 23942892
[TBL] [Abstract][Full Text] [Related]
37. Fertility preservation among young breast cancer patients: A single-center experience in China.
Wan Q; Han L; Liu J; Li H; Li Y; Long QM; Tan L; Li JJ
Taiwan J Obstet Gynecol; 2021 Sep; 60(5):827-830. PubMed ID: 34507656
[TBL] [Abstract][Full Text] [Related]
38. Gonadotropin-releasing hormone agonist trigger increases the number of oocytes and embryos available for cryopreservation in cancer patients undergoing ovarian stimulation for fertility preservation.
Pereira N; Kelly AG; Stone LD; Witzke JD; Lekovich JP; Elias RT; Schattman GL; Rosenwaks Z
Fertil Steril; 2017 Sep; 108(3):532-538. PubMed ID: 28865552
[TBL] [Abstract][Full Text] [Related]
39. Ovarian stimulation is a safe and effective fertility preservation option in the adolescent and young adult population.
Manuel SL; Moravek MB; Confino R; Smith KN; Lawson AK; Klock SC; Pavone ME
J Assist Reprod Genet; 2020 Mar; 37(3):699-708. PubMed ID: 31828481
[TBL] [Abstract][Full Text] [Related]
40. What threshold values of antral follicle count and serum AMH levels should be considered for oocyte cryopreservation after in vitro maturation?
Sonigo C; Simon C; Boubaya M; Benoit A; Sifer C; Sermondade N; Grynberg M
Hum Reprod; 2016 Jul; 31(7):1493-500. PubMed ID: 27165625
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
